19/589623

## IAP6 Rec'd PCT/PTO 1 6 AUG 2006 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Lola WEISS et al

Serial No.:

National Phase of PCT/ IL2005/000196

Filed:

Herewith

For:

TREATING OR PREVENTING DIABETES

WITH CANNABIDIOL

į

999999999

Examiner:

Not Yet Assigned

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Group Art Unit: Not Yet Assigned

Attorney

Docket: 32361

## **INFORMATION DISCLOSURE STATEMENT**

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Moynihan

Registration No. 40,338

Dated: July 27, 2006

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number National Phase of PCT/ INFORMATION DISCLOSURE IL2005/000196 STATEMENT BY APPLICANT Filing Date Herewith First Named Inventor Lola WEISS et al (use as many sheets as necessary) Art Unit Not Yet Assigned Examiner Name Not Yet Assigned Attorney Docket Number 32361 2 Sheet of **U.S. PATENT DOCUMENTS** Publication Date Name of Patentee or Pages, Columns, Lines, Where Examiner Document Number MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Initials\* Figures Appear Number-Kind Code<sup>2 (if known)</sup>

11,

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. 1	Foreign Patent Documents Publication Dat MM-DD-YYY  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)		Applicant of Cited Document Where Relevant Pas		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
	1	PCT WO 99/53917	10-28-1999	Hampson et al. Whittle et al.			$\vdash$
	2	PCT WO 03/063847	07-7-2003				
	<u> </u>			<del> </del>			╄
				ļ			$\vdash$
							Т
Examiner Signature					Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.

Traissation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

10/589623 M58 725 3 3 5 7 4 3 1 6 AUG 2006

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number National Phase of INFORMATION DISCLOSURE PCT/ IL2005/000196 STATEMENT BY APPLICANT Filing Date Herewith Lola WEISS et al (use as many sheets as necessary) First Named Inventor Group Art Unit Not Yet Assigned Examiner Name Not Yet Assigned Sheet 2 32361 Attorney Docket Number 32361 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), T<sup>2</sup> Initials No. publisher, city and/or country where published. 3 ??? "Cannabis-Based Medicines - GW Pharmaceuticals: High CBD, High THC, Medicinal Cannabis - GW Pharmaceuticals, THC: CBD", Drugs R&D, 4(5): 306-309, 2003. P.307, 4th Full §. Weiss et al. "Cytokine Production in Linomide-Treated Nod Mice and the Potential 4 Role of A Th1/Th2 Shift on Autoimmune and Anti-Inflammatory Processes", Cytokine, 19(2): 85-93, 2002. Fig. 1, 4, P.87-91, § entitled "Discussion". Srivastava et al. "A9 Tetrahydrocannabinol and Cannabidiol Alter Cytokine 5 Production by Human Immune Cells", Immunopharmacology, 40(3): 179-185, 1998. P.183-184, § entitled "Discussion".

Signature Considered \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.